Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. Ig = immunoglobulin, CRP = C-reactive protein, SAA = serum amyloid A protein. Reprinted, with permission, from reference 21.

Elevated interleukin (IL)-17 levels are increasingly implicated ... Biologic agents targeting IL-6 (such as tocilizumab) are already used in the clinic to treat other autoimmune inflammatory ...

3,4 Tocilizumab products are recombinant humanized monoclonal antibodies that target IL-6 receptors that bind to soluble and membrane-bound IL-6 receptors and inhibit signaling. 3 Patients who ...

Tocilizumab (Actemra, Genentech) is a recombinant humanized monoclonal antibody and IL-6 receptor antagonist. The FDA’s decision was informed by phase 3 study results, presented at ACR ...

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly ... of the COVID-19 crisis before falling back to pre-pandemic levels. Roche’s primary patents on the drug have already ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...